Skip to main content

Fight against pandemics

Women and children’s health

Funding and quality of aid

Research and Development

Opinions

EU Pharma Strategy
Blog series

We believe in alternative funding and pricing models that can encourage pharmaceutical companies to innovate and to charge reasonable prices

By Ella Weggen, Global health advocate at Wemos
EU Pharma Strategy
Blog series

It is clear that transparency creates trust, and that the Political institutions should be irreproachable in that regard

By Tilly Metz, Member of the EU Parliament
EU Pharma Strategy
Blog series

Transparency is key to unlocking better policies

By Ellen T'Hoen, lawyer and director of Medicine Law & Policy